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INTRODUCTION
Chronic kidney disease (CKD) is a largely 
asymptomatic condition of diminished renal 
function.1 It has an estimated prevalence in 
England of 15% in people aged ≥35 years, 
and an estimated annual cost to the NHS of 
1.4 billion GBP.2 CKD prevalence increases 
with age and it is independently associated 
with increased cardiovascular disease risk 
and all-cause mortality.3 Having CKD stage ≥3 
is the leading risk factor for progression to 
end-stage renal disease (ESRD)4 and a strong 
predictor of hospitalisation.5 Globally, CKD 
mortality has increased by one-third over 
the last 10 years, accounting for 1.2 million 
deaths annually worldwide.6
International guidelines, such as those 
from the National Institute for Health and 
Care Excellence (NICE)7 and Kidney Disease: 
Improving Global Outcomes (KDIGO),8 
recommend that people with CKD are 
identified early to address cardiovascular 
risk, slow CKD progression, and reduce the 
numbers reaching ESRD and associated 
costs.9 Many patients in primary care have 
CKD that is not formally recognised, and it is 
unclear whether this has any bearing on their 
prognosis.10
CKD is characterised by measures of 
renal function including increasing urinary 
albumin:creatinine ratio (ACR) or decreasing 
glomerular filtration rate (GFR), estimated 
from serum creatinine (eGFR). In line with 
recommendations from NICE7 and KDIGO,8 
CKD is classified into stages based on eGFR 
and ACR cut-offs. Figure 1, adapted from 
KDIGO guidelines,8 shows the categories 
and increased risk of adverse outcomes 
as CKD stage increases. Many reports of 
CKD prevalence have only used a single 
measurement,11 which may have resulted in 
biased estimates.
Though CKD is usually asymptomatic until 
later stages of the disease (stage ≥4), earlier 
stages (1–3) are associated with increased 
mortality12 and cardiovascular risk.3 It may 
therefore be beneficial to establish efficient 
detection mechanisms for patients with 
early-stage CKD. Screening enables early 
detection, but mass screening of all age 
groups for kidney disease is expensive, of low 
yield, and not cost-effective.13 There is an age-
related decline in renal function and UK data 
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Prevalence of chronic kidney disease in the 
community using data from OxRen:
a UK population-based cohort study
Abstract
Background
Chronic kidney disease (CKD) is a largely 
asymptomatic condition of diminished renal 
function, which may not be detected until 
advanced stages without screening. 
Aim
To establish undiagnosed and overall CKD 
prevalence using a cross-sectional analysis.
Design and setting
Longitudinal cohort study in UK primary care.
Method
Participants aged ≥60 years were invited to attend 
CKD screening visits to determine whether they 
had reduced renal function (estimated glomerular 
filtration rate [eGFR] <60 ml/min/1.73 m2 or 
albumin:creatinine ratio ≥3 mg/mmol). Those with 
existing CKD, low eGFR, evidence of albuminuria, 
or two positive screening tests attended a 
baseline assessment (CKD cohort).
Results
A total of 3207 participants were recruited 
and 861 attended the baseline assessment. 
The CKD cohort consisted of 327 people with 
existing CKD, 257 people with CKD diagnosed 
through screening (CKD prevalence of 18.2%, 
95% confidence interval [CI] = 16.9 to 19.6), and 
277 with borderline/transient decreased renal 
function. In the CKD cohort, 54.4% were female, 
mean standard deviation (SD) age was 74.0 
(SD 6.9) years, and mean eGFR was 58.0 (SD 18.4) 
ml/min/1.73 m2. Of the 584 with confirmed CKD, 
44.0% were diagnosed through screening. Over 
half of the CKD cohort (51.9%, 447/861) fell into 
CKD stages 3–5 at their baseline assessment, 
giving an overall prevalence of CKD stages 3–5 of 
13.9% (95% CI = 12.8 to 15.1). More people had 
reduced eGFR using the Modification of Diet in 
Renal Disease (MDRD) equation than with CKD 
Epidemiology Collaboration (CKD-EPI) equation in 
the 60–75-year age group and more had reduced 
eGFR using CKD-EPI in the ≥80-year age group.
Conclusion
This study found that around 44.0% of people 
living with CKD are undiagnosed without 
screening, and prevalence of CKD stages 1–5 was 
18.2% in participants aged >60 years. Follow-up 
will provide data on annual incidence, rate of CKD 
progression, determinants of rapid progression, 
and predictors of cardiovascular events.
Keywords
chronic kidney diseases; glomerular filtration 
rate; kidney failure; OxRen; prevalence; primary 
health care.
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show that from age 60 years the prevalence 
of CKD stages 3–5 increases rapidly.14,15 It 
may, therefore, be reasonable to consider 
screening systematically in this age group.
The Oxford Renal Longitudinal Cohort 
Study (OxRen) is a prospective observational 
longitudinal cohort study of a primary care 
population aged ≥60 years. The study was 
established by the University of Oxford in 
2013 in the central region of the UK to answer 
important research questions around these 
uncertainties. The key objectives were to 
determine the prevalence, annual incidence, 
and progression of CKD in an older UK 
population to define the prevalence of selected 
risk factors and establish the distribution of 
estimated kidney function in patients detected 
by a targeted screening programme.16 This 
article reports estimates of the proportion 
of people with undiagnosed CKD, overall 
CKD prevalence, and characteristics from the 
OxRen study cohort.
METHOD
Participants aged ≥60 years were recruited 
in 13 primary care clinics across Oxfordshire, 
UK, over 44 months, from November 2013 
to July 2017. Patients were excluded if they 
were unable to give informed consent, were 
terminally ill, had a previous solid organ 
transplant, or if the GP judged them to be 
unable to give consent. Eligible participants 
were invited to attend an initial visit where the 
study was explained and written informed 
consent was obtained. 
Participants entered the OxRen CKD 
cohort either on the basis of an existing 
diagnosis of CKD in their GP records, or 
through screening. Screening visits involved 
a serum creatinine test to calculate eGFR 
and a urinary ACR test. Participants with 
no previous diagnosis of CKD attended a 
screening visit (A). If the screening result 
showed decreased renal function (eGFR 
<65 ml/min/1.73 m2) or evidence of kidney 
damage (ACR ≥3 mg/mmol), the participant 
proceeded to a second screening visit (B) 
after a 3-month interval to have their CKD 
diagnosis confirmed. If after this visit, the 
participant had two abnormal results (eGFR 
<60 ml/min/1.73 m2 or ACR ≥3 mg/mmol), 
they were classified as having CKD and 
invited to attend the baseline assessment 
visit at their GP practice. 
If on the second occasion the eGFR and 
ACR did not fall within the criteria for CKD 
diagnosis, participants were still invited to 
the baseline assessment visit but classified 
as having borderline/transient decreased 
renal function providing their first result 
suggested CKD stage 1–5. Participants who 
had a borderline result in their first test 
and abnormal second test result were also 
classified as having borderline/transient 
decreased renal function and invited to attend 
a baseline assessment. All participants 
invited to the baseline assessment are 
hereafter called the CKD cohort (Figure 2).
How this fits in
Chronic kidney disease (CKD) is a largely 
asymptomatic condition with a reported 
prevalence of around 15% in England in 
people aged ≥35 years. Routine screening 
in older people may detect undiagnosed 
CKD. Using two measurements of serum 
creatinine and urinary albumin, this study 
found the prevalence was 18.2% for any-
stage CKD and 13.9% in stages 3–5 in 
an older primary care population (aged 
≥60 years). Screening using these two 
measurements identified that around 8% of 
older people were living with undiagnosed 
CKD.
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Figure 1. Classification of chronic kidney disease 
(CKD) using glomerular filtration rate (GFR) and 
albumin:creatinine ratio (ACR). 
Adapted from KDIGO guidelines8 with permission 
from Elsevier. A1 = normal albuminuria. A2 = micro-
albuminuria. A3 = macro-albuminuria. G =  stage of 
CKD (1–5) by GFR category. 
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At the baseline assessment visit, data were 
collected on demographics, lifestyle, and 
medical history. Anthropometric and clinical 
measurements (blood pressure and pulse 
wave velocity) were made. Questionnaires 
were completed on diet, physical activity, 
cognitive function, and quality of life. Blood 
and urine samples were sent for immediate 
laboratory analysis, and additional blood and 
urine samples were collected and stored at 
−80°C for future genetic and protein testing. 
All samples were processed across two 
laboratories using identical instrumentation 
and assay standardisation. Serum creatinine 
was measured using an isotope dilution mass 
spectrometry traceable method17 and eGFR 
was reported using the Modification of Diet in 
Renal Disease (MDRD) equation.18 The most 
recent test result was used for 12 participants 
where no results were available at the time of 
the test. The effect of these approximations 
on results was tested by re-analysing data 
excluding these participants from the 
analysis.
Data management and reporting
Participants whose laboratory eGFR was 
reported as >90 ml/min/1.73 m2 (n = 2) were 
Figure 2. Participant flow chart.
aNational Institute for Health and Care Excellence 
criteria for diagnosis of chronic kidney disease 
(CKD): ≥2 results at least 3 months apart. bEstimated 
glomerular filtration rate (eGFR) <60 ml/min/1.73 m2, 
or eGFR >60 ml/min/1.73 m2, and albumin:creatinine 
ratio (ACR) >3 mg/mmol; at least one result must be 
from Screening A or Screening B. 
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designated to have eGFR of 91 ml/ min/1.73 m2. 
Urinary albumin levels were approximated to 
4.9 mg/L for 29 participants whose laboratory 
urinary albumin levels were reported as 
<5 mg/L. These were excluded in a sensitivity 
analysis in two cases where this may have 
changed stage of CKD. CKD stage was 
reported for all participants. Results were 
tabulated for the full CKD cohort and stratified 
both by stage of CKD and how the participant 
entered the cohort (previous diagnosis, new 
diagnosis, or borderline/transient decreased 
renal function) to report prevalence and 
95% confidence intervals (CIs).19,20 The eGFR 
results and stage of CKD were also reported 
using the CKD Epidemiology Collaboration 
(CKD-EPI) equation, which is the global 
standard for estimating GFR for comparison 
purposes, and prevalence of reduced eGFR 
(<60 ml/min/1.73 m2) was compared with 
MDRD across participant age.
All data management and analyses were 
carried out using Stata (version 14SE). Data 
are presented in tables and summarised as 
number and per cent, or mean and standard 
deviation (SD). For continuous variables that 
were non-normally distributed, the median 
and interquartile range (IQR) are reported. 
Data sharing
Requests to access OxRen data should be 
addressed to the corresponding authors. 
Patient and public involvement
A patient representative sits on the Study 
Steering Committee that meets on a 
6-monthly basis to assess the progress of 
participant recruitment and follow-up, to 
review and contribute to study materials, and 
to oversee the ethical and safe conduct of the 
research.
RESULTS
In total, 8268 people were invited to 
participate in OxRen and 3207 were 
recruited (38.8% recruitment rate). Among 
recruited participants, 327 had CKD 
previously documented from GP records 
and 2880 attended screening visits. At 
screening, 534 (18.5%, 534/2880) had 
one or more positive tests for CKD (257 
newly diagnosed, 277 borderline/transient 
decreased renal function). The resulting total 
of 861 participants (26.8% of those recruited) 
entered the CKD cohort and attended 
the baseline assessment. Overall, newly 
diagnosed CKD was 8.0% (257/3207) (95% 
CI = 7.1 to 9.0) and pre-existing CKD was 
10.2% (327/3207) (95% CI = 9.2 to 11.3) giving 
CKD prevalence of 18.2% (584/3207) (95% 
CI = 16.9 to 19.6). Of the 584 with confirmed 
CKD, 44.0% were diagnosed through 
screening (Figure 2).
Characteristics of the 861 participants who 
attended a baseline study visit are shown 
in Table 1. Results are presented for all 
participants and stratified by whether they had 
existing CKD, newly diagnosed, or borderline/
transient decreased renal function. Briefly, 
54.4% were female, mean (SD) age was 
74.0 (SD 6.9) years, mean BMI was 28.1 
(SD 7.3) kg/m2, and 846 (98.3%) were white. 
Prevalence of hypertension was 59.3% and 
diabetes was 15.4%. These, and prevalence of 
other comorbidities, are presented for the full 
cohort and for different subgroups in Tables 1 
and 2, and Supplementary Table S1. 
Stratification by stage of CKD using 
eGFR and ACR shows that 258 participants 
(30.0%) met the KDIGO definition of normal 
kidney function (eGFR ≥60 ml/min/1.73 m2 
and ACR <3 mg/mmol),8 34 participants 
(4.0%) had CKD stage 1, 122 (14.2%) 
had CKD stage 2, 246 (28.6%) had CKD 
stage 3a, 133 (15.5%) had CKD stage 3b, 67 
(7.8%) had CKD stage 4, and one (0.12%) 
had stage 5 CKD. Over half of the CKD 
cohort fell into CKD stages 3–5, which 
gave a prevalence of CKD stages 3–5 of 
13.9% (447/3207) from the full population 
screened (see Table 2 and Supplementary 
Table S1). Results were similar in sensitivity 
analyses where approximations were made 
(see Supplementary Table S2 for details). 
CKD stage of participants stratified by 
entry to the CKD cohort is shown in Figure 3 
and Supplementary Table S3. Sixty-five 
participants with previously diagnosed 
CKD (20%, N = 327), 58 with newly 
diagnosed CKD (23%, N = 257), and 135 
with borderline/transient decreased renal 
function (49%, N = 277) were classified as 
having normal kidney function (by KDIGO 
definition)8 at their baseline visit. Stage of 
CKD and eGFR calculated using the CKD-
EPI equation is shown in Supplementary 
Table S4 and S5, and Supplementary 
Figure S1. Overall, there were more people 
with CKD stages 2 and 4 and fewer people 
with CKD stages 1, 3a, and 3b compared 
with CKD stage calculated using the MDRD 
equation. More people had reduced eGFR 
(<60 ml/min/1.73 m2) using MDRD than 
with CKD-EPI in the 60–75-year age group, 
and more had reduced eGFR using CKD-
EPI in the ≥80-year age group (Figure 4).
DISCUSSION
Summary
This large-scale screening study from UK 
primary care offers a prevalence estimate of 
18.2% (95% CI = 16.9 to 19.6) for CKD stages 
1–5 in people aged ≥60 years and has found 
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Table 1. Patient demographics stratified by screening data
 Full cohort  Existing CKD Newly diagnosed CKD Borderline/transient decreased  
Characteristics (N = 861) (N = 327) (N = 257) renal function (N = 277)
 CKD prevalence, % (95% CI) 18.2 (16.9 to 19.6) 10.2 (9.2 to 11.3) 8.0 (7.1 to 9.0) —
 Mean age, years (SD) 74.0 (6.9) 75.4 (7.0) 73.4 (6.5) 72.7 (6.7)
 Female, n (%) 468 (54.4) 183 (56.0) 124 (48.2) 161 (58.1)
 Mean weight, kg (SD) 78.0 (17.1) 77.3 (16.1) 80.2 (18.0) 76.8 (17.4)
 Mean height, cm (SD) 167.0 (10.5) 167.0 (10.2) 167.8 (10.0) 166.1 (11.2)
 Mean waist circumference, cm (SD) 97.0 (14.6) 97.0 (13.4) 99.0 (15.2) 95.0 (15.1)
 Mean hip circumference, cm (SD) 106.4 (10.7) 106.9 (10.3) 107.0 (11.3) 105.4 (10.4)
 Mean BMI, kg/m2 (SD) 28.1 (7.3) 27.6 (5.1) 28.5 (6.4) 28.2 (9.9)
Ethnicity, n (%)
 White 846 (98.3)a 323 (98.8)  253 (98.4) 271 (97.8)
 Other  14 (1.6) 4 (1.2) 4 (1.6) 6 (2.2)
Educational status, n (%)
 School up to 16 years 483 (56.1) 183 (56.0) 150 (58.4) 150 (54.2)
 Sixth form school or college 174 (20.2) 57 (17.4) 55 (21.4) 62 (22.4)
 University or higher 204 (23.7) 87 (26.6) 52 (20.2) 65 (23.5)
Smoking status, n (%)
 Never 466 (54.1) 171 (52.3) 137 (53.3) 158 (57.0)
 Former  357 (41.5) 142 (43.4) 111 (43.2) 104 (37.5)
 Current 38 (4.4) 14 (4.3) 9 (3.5) 15 (5.4)
Alcohol use, units/week
 None, n (%) 252 (29.3) 85 (26.0) 88 (34.2) 79 (28.5)
 One or more, n (%) 609 (70.7) 242 (74.0) 169 (65.8) 198 (71.5)
 Median (IQR) 2 (0 to 8) 2 (0 to 7) 2 (0 to 9) 3 (0 to 10)
 Mean (SD) 5.9 (8.7) 5.3 (8.0) 6.1 (9.1) 6.4 (9.0)
Major comorbidities, n (%)
 Hypertension 511 (59.3) 213 (65.1) 160 (62.3) 138 (49.8)
 Diabetes 133 (15.4) 71 (21.7) 38 (14.8) 24 (8.7)
 Ischaemic heart disease 145 (16.8) 62 (19.0) 50 (19.5) 33 (11.9)
 Heart failure 39 (4.5) 19 (5.8) 13 (5.1) 7 (2.5)
 Atrial fibrillation 110 (12.8) 50 (15.3) 34 (13.2) 26 (9.4)
 Cerebrovascular disease 73 (8.5) 36 (11.0) 23 (8.9) 14 (5.1)
 Peripheral vascular disease 29 (3.4) 9 (2.8) 9 (3.5) 11 (4.0)
Systolic blood pressure, mmHg
 Median (IQR) 132 (120 to 144) 130 (119 to 142) 135 (123 to 145) 131 (121 to 145)
 Mean (SD) 133 (18) 131 (17) 135 (19) 132 (18)
Diastolic blood pressure, mmHg
 Median (IQR) 78 (71 to 84) 77 (70 to 82) 79 (72 to 85) 78 (71 to 84)
 Mean (SD) 78 (10) 77 (9.9) 79 (11) 78 (10)
Blood and urine test results    
 eGFR, ml/min/1.73 m2
  >60, n (%)  396 (46.0) 84 (25.7) 135 (52.5) 177 (63.9)
  ≤60, n (%)  465 (54.0) 243 (74.3) 122 (47.5) 100 (36.1)
  Median (IQR) 59 (46 to 69) 50 (35 to 61) 61 (48 to 76) 63 (57 to 74)
  Mean (SD) 58.0 (18.4) 48.9 (17.1) 61.4 (18.7) 65.7 (14.6)
 ACR, mg/mmol, N (%) 774 (89.9) 288 (88.1) 239 (93.0) 247 (89.2)
  <3.0, n (%) 489 (63.2) 194 (67.4) 116 (48.5) 214 (86.6)
  ≥3.0, n (%) 285 (36.8) 94 (32.6) 123 (51.5) 148 (59.9)
  Median (IQR) 2.0 (0.9 to 4.8) 1.6 (0.6 to 4.2) 3.1 (1.3 to 7.5) 1.6 (0.9 to 3.4)
  Mean (SD) 5.2 (11.4) 5.1 (12.3) 7.8 (14.6) 2.8 (3.6)
Questionnaires, n completed (%)
 Quality of life 859 (99.8) 327 (100.0) 256 (99.6) 276 (99.6)
 Diet 310 (36.0)  148 (45.3) 79 (30.7) 83 (30.0)
 Physical activity 736 (85.5) 318 (97.2) 205 (79.8) 213 (76.9)
 Cognitive assessment 625 (72.6) 249 (76.1) 182 (70.8) 194 (70.0)
aData missing for one patient. ACR = albumin:creatinine ratio. BMI = body mass index. CI = confidence interval. CKD = chronic kidney disease. eGFR = estimated glomerular 
filtration rate. IQR = interquartile range. SD = standard deviation.
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that 8.0% of this population had CKD that 
was previously undiagnosed. More than 
half (51.3%) of those with only a single 
positive CKD screening test (borderline/
transient decreased renal function group), 
thus not meeting the diagnostic criteria for 
CKD, were classified into CKD stages 1–4 
at the baseline assessment. Providing the 
baseline samples were taken a minimum of 
12 weeks from their previous positive test, 
these participants now technically meet the 
diagnostic criteria for CKD.8 
Strengths and limitations
This study is methodologically strong, using 
both MDRD and CKD-EPI equations to 
calculate eGFR and including urinary ACR 
to estimate CKD prevalence unlike many 
previous registry studies, which have had 
less urinary ACR data available. This study 
reports CKD prevalence by stage of CKD and 
found that more participants were classified 
into CKD stage 3a than any other CKD 
stage. Furthermore, over one-fifth (21.1%) 
of those with existing CKD were classed as 
having normal renal function from analysis 
of blood and urine samples taken at their 
baseline visit. This highlights how the 
variability in both eGFR and ACR can result 
in some participants, who had previously 
met the diagnostic criteria for CKD, falling 
into the normal kidney function range on 
repeat testing. This suggests that there 
is potential for disease misclassification, 
which could be an artefact of the interval 
between screening visits.21 As more 
laboratories move away from MDRD to use 
other equations for estimating GFR,7,22,23 
the CKD stage for some individuals may 
change, and others may no longer meet 
criteria for diagnosis.22 Findings from this 
study corroborate those from other studies, 
in that moving to CKD-EPI will result in a 
greater proportion of people aged >75 years 
having decreased eGFR compared with 
MDRD and fewer people aged <75 years 
with reduced eGFR.14,24 This analysis has 
also quantified how moving to the CKD-EPI 
equation may lead to classification into a 
different CKD stage for some participants.
There are some limitations to this study. 
It is possible that people who were aware 
that they had CKD were more likely to agree 
to participate in the study, which may have 
led to an overestimation in the prevalence 
of CKD in this cohort. Over 98% of the 
OxRen cohort were white, which is a higher 
proportion than the 95% white ethnicity 
reported in the general UK population 
aged ≥60 years.25 This is also higher than 
Table 2. Patient demographics stratified by CKD stage, N = 860a
 Normal kidney CKD stage 1 CKD stage 2  CKD stage 3a CKD stage 3b CKD stage 4 
Characteristics function (N = 258) (N = 34) (N = 122) (N = 246) (N = 133) (N = 67)
Mean age, years (SD) 72.6 (6.7) 70.6 (4.8) 73.6 (7.3) 74.5 (6.3) 75.7 (7.2) 76.3 (7.2)
Female, n (%) 158 (61.2) 13 (38.2) 54 (44.3) 132 (53.7) 76 (57.1) 34 (50.7)
Weight, kg (SD) 76.6 (16.9) 79.9 (23.4) 76.6 (17.2) 78.6 (17.2) 79.1 (16.5) 80.8 (15.1)
Height, cm (SD) 167.0 (10.7) 169.1 (9.3) 166.8 (10.4) 166.8 (10.5) 167.0 (9.7) 167.2 (12.1)
Waist circumference, cm (SD) 95.5 (15.3) 97.3 (18.5) 95.1 (15.4) 97.5 (13.7) 98.6 (13.3) 100.8 (12.7)
Hip circumference, cm (SD) 105.8 (11.1) 102.4 (10.5) 104.1 (9.7) 107.0 (9.9) 108.4 (11.1) 109.2 (11.3)
BMI, kg/m2 (SD) 27.4 (5.8) 27.6 (6.6) 27.7 (7.7) 28.4 (9.1) 28.3 (5.4) 29.3 (8.3)
Ethnicity, n (%)
 White 254 (98.4) 34 (100.0) 120 (98.4) 239 (97.2)b 132 (99.2) 66 (98.5)
 Other 4 (1.6) – 2 (1.6) 6 (2.4) 1 (0.8) 1 (1.5)
aOne participant with CKD stage 5 not included. bData missing for one patient. BMI = body mass index. CKD = chronic kidney disease. SD = standard deviation.
Figure 3. Chronic kidney disease (CKD) stage of 
participants stratified by entry to the cohort calculated 
using the Modification of Diet in Renal Disease (MDRD) 
equation.
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the rest of Oxfordshire where 92% of the 
population is white.26 The low percentage 
of ethnic minority participants in the cohort 
may have affected the CKD prevalence. Some 
reports suggest that South Asians have a 
lower prevalence of CKD when compared 
with white individuals after adjustment for 
age and sex.27 However, Asian and African 
and Caribbean populations with diabetes 
have been reported to show the most rapid 
decline in renal function28 and African 
and Caribbean populations have a high 
incidence of ESRD.28,29 There were relatively 
low numbers of people with CKD stage 1, 
4, and 5 in the present cohort, but these 
low numbers are also seen in the general 
population.2,30
Despite efforts to recruit GP practices 
in Oxfordshire with different indexes of 
deprivation profiles to ensure comparability 
with the general UK population, recruitment 
took place over a single UK county, which 
may not be fully representative of the 
general UK population. The proportion 
of people with university education 
or above is 18% in the UK population 
aged >65 years31 compared with 24% in 
the OxRen population. However, younger 
age groups in the general population have 
a greater proportion achieving the highest 
level of educational attainment and fewer 
people leaving school with no qualifications 
compared with older age groups.31 As these 
populations age, findings from the cohort 
may be generalisable to these age groups 
after accounting for lifestyle factors. Both 
lower education and socioeconomic status 
are associated with higher prevalence of 
CKD.32
Comparison with existing literature
UK prevalence of CKD stages 1–5 in people 
aged 65–74 years has been reported to be 
19%,2 which is similar to prevalence found 
in the OxRen cohort. For those >75 years of 
age, prevalence reaches 46%.2 A systematic 
review and meta-analysis reporting global 
prevalence of CKD stratified by age found 
a prevalence of CKD stages 1–5 of nearly 
28% in populations with a mean age of 
>60 years and around 34% in those with a 
mean age of 70 years.30 These are higher 
than the prevalence of 18% in the present 
study, which may reflect differences in the 
diagnostic criteria used, or prevalence in 
different ethnic groups and socio-economic 
status.32 Other English data suggest that 
prevalence of CKD stages 3–5 is 12.0–14.5% 
in those aged 65–74 years.2,33 This is similar 
to the 13.9% (95% CI = 12.8 to 15.1) found 
in the OxRen cohort despite these surveys 
using a single eGFR test to classify CKD, 
which has been shown to overestimate 
CKD.10,22 Internationally, most prevalence 
estimates in similar age groups are only 
based on a single test result.11,34,35 In Europe, 
prevalence differs between countries and 
ranges from 24% in Norway to 41% in 
Germany.11 In the US, prevalence of stages 
3–4 is 23%,34 and stages 1–5 of 34%.35
A recently published analysis of 
participants in the OxRen cohort22 found 
that using a single screening test to 
diagnose CKD would result in around 25% 
over diagnosis because of variability in ACR 
and eGFR. The results from laboratory 
analyses at participants’ baseline visit show 
that some participants’ CKD stage can 
revert to normal kidney function despite a 
recent diagnosis. This was observed in 21% 
of OxRen participants who had received 
a CKD diagnosis but tested as normal 
kidney function, based on samples taken 
during their baseline visit. A combination 
of analytical and biological variability may 
have contributed to this.36 These numbers 
are consistent with a previous report that 
found CKD remission rates of 20–30% in 
follow-up visits in primary care populations 
with CKD.37
Implications for research and practice
This study has found that 8.0% of participants 
aged ≥60 years had undiagnosed CKD, 
equating to 44.0% of people living with 
CKD in this population, and would have 
remained undiagnosed without screening. 
This suggests that the early stages of CKD 
(stages 1–3b) may be under-reported in 
the literature as many people are unaware 
that they have the condition.10,38 In the UK, 
some of these people will be picked up in 
Figure 4. Participant eGFR using the Modification of 
Diet in Renal Disease (MDRD) equation and the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation stratified by age. CKD = chronic kidney disease. 
eGFR = estimated glomerular filtration rate.
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the NHS Health Check Programme (www.
healthcheck.nhs.uk), which is a 5-yearly 
free check-up available for adults in the 
UK aged 40–74 years. However, only 43% 
of those invited for an NHS Health Check 
are reported to attend,39 and it is likely that 
many non-attenders will be those most at 
risk.40
OxRen provides an estimate of 
undiagnosed CKD in the UK population 
aged ≥60 years, including screen-detected 
rates, and will provide future estimates 
of incidence. Follow-up will provide 
evidence on the progression of CKD, and, 
if progression occurs, identify groups that 
are most likely to progress, which will make 
it possible to explore associations with 
comorbidities and treatments. 
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